201 related articles for article (PubMed ID: 26298771)
1. Association between TERT promoter polymorphisms and acute myeloid leukemia risk and prognosis.
Mosrati MA; Willander K; Falk IJ; Hermanson M; Höglund M; Stockelberg D; Wei Y; Lotfi K; Söderkvist P
Oncotarget; 2015 Sep; 6(28):25109-20. PubMed ID: 26298771
[TBL] [Abstract][Full Text] [Related]
2. Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis.
Spiegl-Kreinecker S; Lötsch D; Ghanim B; Pirker C; Mohr T; Laaber M; Weis S; Olschowski A; Webersinke G; Pichler J; Berger W
Neuro Oncol; 2015 Sep; 17(9):1231-40. PubMed ID: 25681309
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic landscape of the TERT promoter: a potential biomarker for high risk AML/MDS.
Zhao X; Tian X; Kajigaya S; Cantilena CR; Strickland S; Savani BN; Mohan S; Feng X; Keyvanfar K; Dunavin N; Townsley DM; Dumitriu B; Battiwalla M; Rezvani K; Young NS; Barrett AJ; Ito S
Br J Haematol; 2016 Nov; 175(3):427-439. PubMed ID: 27433923
[TBL] [Abstract][Full Text] [Related]
4. The association between the TERT rs2736100 AC genotype and reduced risk of upper tract urothelial carcinomas in a Han Chinese population.
Yuan X; Meng Y; Li P; Ge N; Kong F; Yang L; Björkholm M; Zhao S; Xu D
Oncotarget; 2016 May; 7(22):31972-9. PubMed ID: 26934125
[TBL] [Abstract][Full Text] [Related]
5. TERT promoter mutations and rs2853669 polymorphism: prognostic impact and interactions with common alterations in glioblastomas.
Nencha U; Rahimian A; Giry M; Sechi A; Mokhtari K; Polivka M; Schmitt Y; Di Stefano AL; Alentorn A; Labussière M; Sanson M
J Neurooncol; 2016 Feb; 126(3):441-6. PubMed ID: 26608520
[TBL] [Abstract][Full Text] [Related]
6. Mutational spectrum and risk stratification of intermediate-risk acute myeloid leukemia patients based on next-generation sequencing.
Wang B; Liu Y; Hou G; Wang L; Lv N; Xu Y; Xu Y; Wang X; Xuan Z; Jing Y; Li H; Jin X; Deng A; Wang L; Gao X; Dou L; Liang J; Chen C; Li Y; Yu L
Oncotarget; 2016 May; 7(22):32065-78. PubMed ID: 27062340
[TBL] [Abstract][Full Text] [Related]
7. The lincRNA HOTAIRM1, located in the HOXA genomic region, is expressed in acute myeloid leukemia, impacts prognosis in patients in the intermediate-risk cytogenetic category, and is associated with a distinctive microRNA signature.
Díaz-Beyá M; Brunet S; Nomdedéu J; Pratcorona M; Cordeiro A; Gallardo D; Escoda L; Tormo M; Heras I; Ribera JM; Duarte R; de Llano MP; Bargay J; Sampol A; Nomdedeu M; Risueño RM; Hoyos M; Sierra J; Monzo M; Navarro A; Esteve J;
Oncotarget; 2015 Oct; 6(31):31613-27. PubMed ID: 26436590
[TBL] [Abstract][Full Text] [Related]
8. The prognostic impact of TERT promoter mutations in glioblastomas is modified by the rs2853669 single nucleotide polymorphism.
Batista R; Cruvinel-Carloni A; Vinagre J; Peixoto J; Catarino TA; Campanella NC; Menezes W; Becker AP; de Almeida GC; Matsushita MM; Clara C; Neder L; Viana-Pereira M; Honavar M; Castro L; Lopes JM; Carvalho B; Vaz RM; Máximo V; Soares P; Sobrinho-Simões M; Reis RM; Lima J
Int J Cancer; 2016 Jul; 139(2):414-23. PubMed ID: 26914704
[TBL] [Abstract][Full Text] [Related]
9. TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations.
Labussière M; Di Stefano AL; Gleize V; Boisselier B; Giry M; Mangesius S; Bruno A; Paterra R; Marie Y; Rahimian A; Finocchiaro G; Houlston RS; Hoang-Xuan K; Idbaih A; Delattre JY; Mokhtari K; Sanson M
Br J Cancer; 2014 Nov; 111(10):2024-32. PubMed ID: 25314060
[TBL] [Abstract][Full Text] [Related]
10. The TERT promoter mutation incidence is modified by germline TERT rs2736098 and rs2736100 polymorphisms in hepatocellular carcinoma.
Yuan X; Cheng G; Yu J; Zheng S; Sun C; Sun Q; Li K; Lin Z; Liu T; Li P; Xu Y; Kong F; Bjorkholm M; Xu D
Oncotarget; 2017 Apr; 8(14):23120-23129. PubMed ID: 28416747
[TBL] [Abstract][Full Text] [Related]
11. Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor.
Wagner K; Damm F; Göhring G; Görlich K; Heuser M; Schäfer I; Ottmann O; Lübbert M; Heit W; Kanz L; Schlimok G; Raghavachar AA; Fiedler W; Kirchner HH; Brugger W; Zucknick M; Schlegelberger B; Heil G; Ganser A; Krauter J
J Clin Oncol; 2010 May; 28(14):2356-64. PubMed ID: 20368538
[TBL] [Abstract][Full Text] [Related]
12. Clinical characteristics and prognostic study of adult acute myeloid leukemia patients with
Lin Y; Wang Y; Zheng Y; Wang Z; Wang Y; Wang S
Hematology; 2020 Dec; 25(1):446-456. PubMed ID: 33250015
[No Abstract] [Full Text] [Related]
13. TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism.
Rachakonda PS; Hosen I; de Verdier PJ; Fallah M; Heidenreich B; Ryk C; Wiklund NP; Steineck G; Schadendorf D; Hemminki K; Kumar R
Proc Natl Acad Sci U S A; 2013 Oct; 110(43):17426-31. PubMed ID: 24101484
[TBL] [Abstract][Full Text] [Related]
14. TERT rs2853669 as a predictor for overall survival in patients with acute myeloid leukaemia.
Tripon F; Bănescu C; Trifa AP; Crauciuc AG; Moldovan VG; Boglis A; Benedek I; Demian S; Duicu C; Iancu M
Arch Med Sci; 2022; 18(1):103-111. PubMed ID: 35154531
[TBL] [Abstract][Full Text] [Related]
15. TERT genetic variability and telomere length as factors affecting survival and risk in acute myeloid leukaemia.
Dratwa M; Wysoczańska B; Butrym A; Łacina P; Mazur G; Bogunia-Kubik K
Sci Rep; 2021 Dec; 11(1):23301. PubMed ID: 34857839
[TBL] [Abstract][Full Text] [Related]
16. Co-occurrence of Myeloproliferative Neoplasms and Solid Tumors Is Attributed to a Synergism Between Cytoreductive Therapy and the Common TERT Polymorphism rs2736100.
Krahling T; Balassa K; Kiss KP; Bors A; Batai A; Halm G; Egyed M; Fekete S; Remenyi P; Masszi T; Tordai A; Andrikovics H
Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):98-104. PubMed ID: 26487696
[TBL] [Abstract][Full Text] [Related]
17. TERT promoter mutations in soft tissue sarcomas.
Campanella NC; Penna V; Abrahão-Machado LF; Cruvinel-Carloni A; Ribeiro G; Soares P; Scapulatempo-Neto C; Reis RM
Int J Biol Markers; 2016 Feb; 31(1):e62-7. PubMed ID: 26391479
[TBL] [Abstract][Full Text] [Related]
18. Telomerase reverse transcriptase (TERT) A1062T mutation as a prognostic factor in Egyptian patients with acute myeloid leukemia (AML).
Aref S; El-Ghonemy MS; Abouzeid TE; El-Sabbagh AM; El-Baiomy MA
Med Oncol; 2014 Sep; 31(9):158. PubMed ID: 25108601
[TBL] [Abstract][Full Text] [Related]
19. 5-Hydroxymethylcytosine correlates with epigenetic regulatory mutations, but may not have prognostic value in predicting survival in normal karyotype acute myeloid leukemia.
Ahn JS; Kim HJ; Kim YK; Lee SS; Ahn SY; Jung SH; Yang DH; Lee JJ; Park HJ; Choi SH; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Michael S; Minden MD; Kim DD
Oncotarget; 2017 Jan; 8(5):8305-8314. PubMed ID: 28039446
[TBL] [Abstract][Full Text] [Related]
20. TERT promoter mutations and polymorphisms as prognostic factors in primary glioblastoma.
Mosrati MA; Malmström A; Lysiak M; Krysztofiak A; Hallbeck M; Milos P; Hallbeck AL; Bratthäll C; Strandéus M; Stenmark-Askmalm M; Söderkvist P
Oncotarget; 2015 Jun; 6(18):16663-73. PubMed ID: 26143636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
